OOIR: Observatory of International Research

Papers

(The TQCC of Movement Disorders is 11. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)

Article	Citations
The Movement Disorder Society Criteria for the Diagnosis of Multiple System Atrophy	238
Meta‐Analysis of Gut Dysbiosis in Parkinson's Disease	204
Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease	180
Outcome of Parkinson's Disease Patients Affected by COVID‐19	179
Effects of COVID‐19 on Parkinson's Disease Clinical Features: A Community‐Based Case‐Control Study	142
Ten Unsolved Questions About Neuroinflammation in Parkinson's Disease	131
COVID‐19 in Parkinson’s Disease Patients Living in Lombardy, Italy	122
Mental Health, Physical Activity, and Quality of Life in Parkinson's Disease During COVID‐19 Pandemic	122
Type 2 Diabetes as a Determinant of Parkinson's Disease Risk and Progression	108
Genome‐Wide Association Studies of Cognitive and Motor Progression in Parkinson's Disease	107
Validation of Serum Neurofilament Light Chain as a Biomarker of Parkinson's Disease Progression	105
Coronavirus Disease 2019 and Parkinsonism: A Non‐post‐encephalitic Case	92
Rapid Onset Functional Tic‐Like Behaviors in Young Females During the COVID‐19 Pandemic	89
Parkinson's Disease and COVID‐19: Perceptions and Implications in Patients and Caregivers	89
Guidelines for Speech Recording and Acoustic Analyses in Dysarthrias of Movement Disorders	87
Blinded RT‐QuIC Analysis of α‐Synuclein Biomarker in Skin Tissue From Parkinson's Disease Patients	86
GBA‐Related Parkinson's Disease: Dissection of Genotype–Phenotype Correlates in a Large Italian Cohort	83
Incidence of Anxiety in Parkinson's Disease During the Coronavirus Disease (COVID‐19) Pandemic	83
Genotype–Phenotype Relations for Isolated Dystonia Genes: MDSGene Systematic Review	79
GP2: The Global Parkinson's Genetics Program	79
Neuroimaging of Anxiety in Parkinson's Disease: A Systematic Review	74
Global Survey on Telemedicine Utilization for Movement Disorders During the COVID‐19 Pandemic	74
Genetic and Environmental Factors in Parkinson's Disease Converge on Immune Function and Inflammation	72
Integrated Care in Parkinson's Disease: A Systematic Review and Meta‐Analysis	70
The Parkinson's Disease Genome‐Wide Association Study Locus Browser	69

Neurofilament Light Chain as a Biomarker for Cognitive Decline in Parkinson Disease	67
Validation of α‐Synuclein in L1CAM‐Immunocaptured Exosomes as a Biomarker for the Stratification of Parkinsonian Syndromes	67
Synaptic Loss in Primary Tauopathies Revealed by [¹¹C]UCB‐J Positron Emission Tomography	65
Tryptophan Metabolites Are Associated With Symptoms and Nigral Pathology in Parkinson's Disease	65
The Role of Cholesterol in α‐Synuclein and Lewy Body Pathology in GBA1 Parkinson's Disease	62
Nonsteroidal Anti‐inflammatory Use and LRRK2 Parkinson's Disease Penetrance	59
Accelerating Medicines Partnership: Parkinson's Disease. Genetic Resource	57
RT‐QuIC Detection of Pathological α‐Synuclein in Skin Punches of Patients with Lewy Body Disease	57
Bilateral Focused Ultrasound Thalamotomy for Essential Tremor (BEST‐FUS Phase 2 Trial)	56
GBA Variants in Parkinson's Disease: Clinical, Metabolomic, and Multimodal Neuroimaging Phenotypes	56
A Novel SNCA A30G Mutation Causes Familial Parkinsonʼs Disease	55
Pandemic Tic‐like Behaviors Following Social Media Consumption	55
Coronavirus Disease 2019 Case Fatality and Parkinson's Disease	54
Loss of Presynaptic Terminal Integrity in the Substantia Nigra in Early Parkinson's Disease	54
A Phase 1 Randomized Trial of Specific Active α‐Synuclein Immunotherapies PD01A and PD03A in Multiple System Atrophy	54
International Multicenter Analysis of Brain Structure Across Clinical Stages of Parkinson's Disease	54
European Academy of Neurology/Movement Disorder Society‐European Section Guideline on the Treatment of Parkinson's Disease: I. Invasive Therapies	54
Longitudinal Changes in Neuromelanin MRI Signal in Parkinson's Disease: A Progression Marker	53
α‐Synuclein in Plasma‐Derived Extracellular Vesicles Is a Potential Biomarker of Parkinson's Disease	53
Assessment of Ataxia Rating Scales and Cerebellar Functional Tests: Critique and Recommendations	53
Parkinson's Disease and Post–COVID‐19 Syndrome: The Parkinson's Long‐COVID Spectrum	53
Differences in the Presentation and Progression of Parkinson's Disease by Sex	53
Systematic Assessment of 10 Biomarker Candidates Focusing on α‐Synuclein‐Related Disorders	52
Closed‐Loop Deep Brain Stimulation for Essential Tremor Based on Thalamic Local Field Potentials	52
Electroconvulsive Therapy for Parkinson's Disease: A Systematic Review and Meta‐Analysis	52
Nomenclature of Genetic Movement Disorders: Recommendations of the International Parkinson and Movement Disorder Society Task Force – An Update	51
Brain Microglial Activation Increased in Glucocerebrosidase (GBA) Mutation Carriers without Parkinson's disease	51
The Rostock International Parkinson's Disease (ROPAD) Study: Protocol and Initial Findings	51
MIND and Mediterranean Diets Associated with Later Onset of Parkinson's Disease	50
Continuous Dopaminergic Stimulation as a Treatment for Parkinson's Disease: Current Status and Future Opportunities	50
GBA and APOE Impact Cognitive Decline in Parkinson's Disease: A 10‐Year Population‐Based Study	50
Global and Regional Changes in Perivascular Space in Idiopathic and Familial Parkinson's Disease	50
Skin Biopsy May Help to Distinguish Multiple System Atrophy–Parkinsonism from Parkinson's Disease With Orthostatic Hypotension	49
Penetrance of Glucocerebrosidase (GBA) Mutations in Parkinson's Disease: A Kin Cohort Study	49
Helicobacter pylori Eradication in Parkinson's Disease: A Randomized Placebo‐Controlled Trial	49
Impact of Coronavirus Disease 2019 Pandemic on Parkinson's Disease: A Cross‐Sectional Survey of 568 Spanish Patients	48
Bacterial Butyrate in Parkinson's Disease Is Linked to Epigenetic Changes and Depressive Symptoms	48
Cortical [¹⁸F]PI‐2620 Binding Differentiates Corticobasal Syndrome Subtypes	48
Risk of Hospitalization and Death for COVID‐19 in People with Parkinson's Disease or Parkinsonism	47
Prevalence of Parkinson's Disease: A Community‐Based Study in China	46
Clinical Utility of ¹⁸F‐APN‐1607 Tau PET Imaging in Patients with Progressive Supranuclear Palsy	45
A Large‐Scale Full GBA1 Gene Screening in Parkinson's Disease in the Netherlands	43
Prevalence and Incidence of Huntington's Disease: An Updated Systematic Review and Meta‐Analysis	43
Reduced Synaptic Density in Patients with Lewy Body Dementia: An [¹¹C]UCB‐J PET Imaging Study	42
Cholinergic Denervation Patterns Across Cognitive Domains in Parkinson's Disease	42
Prodromal Spinocerebellar Ataxia Type 2 Subjects Have Quantifiable Gait and Postural Sway Deficits	42
Diabetes Causes Dysfunctional Dopamine Neurotransmission Favoring Nigrostriatal Degeneration in Mice	42
Development and Validation of a Patient‐Reported Outcome Measure of Ataxia	42
A Critical Review of White Matter Changes in Huntington’s Disease	42
Dopamine Receptors in Parkinson's Disease: A Meta‐Analysis of Imaging Studies	41

Mediterranean Dietary Pattern at Middle Age and Risk of Parkinson's Disease: A Swedish Cohort Study	41
The Mutation Matters: CSF Profiles of GCase, Sphingolipids, α‐Synuclein in PD_GBA	40
Parkinson's Disease Phenotypes in Patient Neuronal Cultures and Brain Organoids Improved by 2‐Hydroxypropyl‐β‐Cyclodextrin Treatment	40
Tracking Cortical Changes Throughout Cognitive Decline in Parkinson's Disease	40
A Randomized, Controlled Trial of Exercise for Parkinsonian Individuals With Freezing of Gait	39
Peripheral Immune Profile and Neutrophil‐to‐Lymphocyte Ratio in Parkinson's Disease	39
Detecting Sensitive Mobility Features for Parkinson's Disease Stages Via Machine Learning	39
Cannabidiol for Rapid Eye Movement Sleep Behavior Disorder	38
The Possible Protective Role of α‐Synuclein Against Severe Acute Respiratory Syndrome Coronavirus 2 Infections in Patients With Parkinson's Disease	38
Differentially Expressed Circular RNAs in Peripheral Blood Mononuclear Cells of Patients with Parkinson's Disease	38
Diagnostic Value of Salivary Real‐Time Quaking‐Induced Conversion in Parkinson's Disease and Multiple System Atrophy	38
Serotonergic and Dopaminergic Lesions Underlying Parkinsonian Neuropsychiatric Signs	38
Soluble CD163 Changes Indicate Monocyte Association With Cognitive Deficits in Parkinson's Disease	37
A New Day: The Role of Telemedicine in Reshaping Care for Persons With Movement Disorders	37
Cognitive Determinants of Dysarthria in Parkinson's Disease: An Automated Machine Learning Approach	37
Analysis of Heterozygous PRKN Variants and Copy‐Number Variations in Parkinson's Disease	37
Efficacy of Omaveloxolone in Friedreich's Ataxia: Delayed‐Start Analysis of the MOXIe Extension	37
Regional Brain and Spinal Cord Volume Loss in Spinocerebellar Ataxia Type 3	36
The Impact of COVID‐19 on Access to Parkinson's Disease Medication	36
Unmet Needs of Women Living with Parkinson's Disease: Gaps and Controversies	36
Development of SARA^home, a New Video‐Based Tool for the Assessment of Ataxia at Home	36
In Vivo Assessment of Neuroinflammation in 4‐Repeat Tauopathies	36
Stress and Mindfulness in Parkinson's Disease: Clinical Effects and Potential Underlying Mechanisms	36
Levodopa Dose Equivalency in Parkinson's Disease: Updated Systematic Review and Proposals	35
α‐Synuclein Spread from Olfactory Bulb Causes Hyposmia, Anxiety, and Memory Loss in BAC‐SNCA Mice	35
The Impact of Type 2 Diabetes in Parkinson's Disease	35
Action Observation and Motor Imagery Improve Dual Task in Parkinson's Disease: A Clinical/fMRI Study	35
The Neurophysiology of Sleep in Parkinson's Disease	35
Expiratory Muscle Strength Training for Therapy of Pharyngeal Dysphagia in Parkinson's Disease	35
Genotype–Phenotype Relations in Primary Familial Brain Calcification: Systematic MDSGene Review	35
Plasma Phospho‐Tau Identifies Alzheimer's Co‐Pathology in Patients with Lewy Body Disease	34
CSF NFL in a Longitudinally Assessed PD Cohort: Age Effects and Cognitive Trajectories	34
Clinical Profiles and Mortality of COVID‐19 Inpatients with Parkinson's Disease in Germany	34
Gait Variability in Spinocerebellar Ataxia Assessed Using Wearable Inertial Sensors	34
Air Pollution and the Risk of Parkinson's Disease: A Review	34
Subjective Cognitive Complaint in Parkinson's Disease Patients With Normal Cognition: Canary in the Coal Mine?	34
Movement Disorder Society–Unified Parkinson's Disease Rating Scale Use in the Covid‐19 Era	34
Long‐Term Safety and Clinical Effects of Nilotinib in Parkinson's Disease	33
Alpha and Beta Synucleins: From Pathophysiology to Clinical Application as Biomarkers	33
Abstracts	33
Parkin Deficiency Impairs Mitochondrial DNA Dynamics and Propagates Inflammation	33
Voice Analysis with Machine Learning: One Step Closer to an Objective Diagnosis of Essential Tremor	33
Dissecting the Phenotype and Genotype of PLA2G6‐Related Parkinsonism	33
Immunohistochemical Detection of Synuclein Pathology in Skin in Idiopathic Rapid Eye Movement Sleep Behavior Disorder and Parkinsonism	32
Brain Structural Changes in Focal Dystonia—What About Task Specificity? A Multimodal MRI Study	32
Seven Solutions for Neuroprotection in Parkinson's Disease	32
Recent Advances in the Development of Stem‐Cell‐Derived Dopaminergic Neuronal Transplant Therapies for Parkinson's Disease	32
Modernizing Daily Function Assessment in Parkinson's Disease Using Capacity, Perception, and Performance Measures	32
How Does Deep Brain Stimulation Change the Course of Parkinson's Disease?	31
Impact of Obstructive Sleep Apnea on Cognitive and Motor Functions in Parkinson's Disease	31
Covid‐19 Infection and Parkinsonism: Is There a Link?	31
Mitochondrial and Clearance Impairment in p.D620N VPS35 Patient‐Derived Neurons	31
The Gut Metabolite Trimethylamine N‐oxide Is Associated With Parkinson's Disease Severity and Progression	30
Four‐Year Follow‐up of [¹⁸F]Fluorodeoxyglucose Positron Emission Tomography–Based Parkinson's Disease–Related Pattern Expression in 20 Patients with Isolated Rapid Eye Movement S	30
Evaluating the Role of SNCA, LRRK2, and GBA in Chinese Patients With Early‐Onset Parkinson's Disease	30
Common Variants Coregulate Expression of GBA and Modifier Genes to Delay Parkinson's Disease Onset	30
Magnetic Resonance Imaging Biomarkers Distinguish Normal Pressure Hydrocephalus From Progressive Supranuclear Palsy	30
Parkinson's Disease Is Associated with Impaired Gut–Blood Barrier for Short‐Chain Fatty Acids	30
Neurofilament Light Chain Predicts Disease Severity and Progression in Multiple System Atrophy	30
The Logic and Pitfalls of Parkinson's Disease as “Brain‐First” Versus “Body‐First” Subtypes	29
Abstracts of the MDS Virtual Congress 2021	29
Asymmetric Dopamine Transporter Loss Affects Cognitive and Motor Progression in Parkinson's Disease	29
Locus Coeruleus Integrity from 7 T MRI Relates to Apathy and Cognition in Parkinsonian Disorders	29
Visual Dysfunction Predicts Cognitive Impairment and White Matter Degeneration in Parkinson's Disease	29
Locus Coeruleus Shows a Spatial Pattern of Structural Disintegration in Parkinson's Disease	29
Altered Cholinergic Innervation in De Novo Parkinson's Disease with and Without Cognitive Impairment	29
The Phenotypic and Genetic Spectrum of Paroxysmal Kinesigenic Dyskinesia in China	29
Impact of Coronavirus Disease 2019 Pandemic on Cognition in Parkinson's Disease	29
Age at Onset of LRRK2 p.Gly2019Ser Is Related to Environmental and Lifestyle Factors	29
Apathy Induced by Subthalamic Nucleus Deep Brain Stimulation in Parkinson's Disease: A Meta‐Analysis	29
Dynamics of Top‐Down Control and Motor Networks in Parkinson's Disease	29
Functional Connectomics and Disease Progression in Drug‐Naïve Parkinson's Disease Patients	29
Monoacylglycerol Lipase Inhibition in Tourette Syndrome: A 12‐Week, Randomized, Controlled Study	28
Automated Categorization of Parkinsonian Syndromes Using Magnetic Resonance Imaging in a Clinical Setting	28
Allogeneic Bone Marrow–Derived Mesenchymal Stem Cell Safety in Idiopathic Parkinson's Disease	28
Decoupling of Global Brain Activity and Cerebrospinal Fluid Flow in Parkinson's Disease Cognitive Decline	28
Resting‐State Functional Connectivity Predicts STN DBS Clinical Response	28
Increased Menopausal Age Reduces the Risk of Parkinson's Disease: A Mendelian Randomization Approach	28
Striatal Blood–Brain Barrier Opening in Parkinson's Disease Dementia: A Pilot Exploratory Study	28
Pedunculopontine Nucleus Microstructure Predicts Postural and Gait Symptoms in Parkinson's Disease	28

CD4+ T‐cell Transcription Factors in Idiopathic REM Sleep Behavior Disorder and Parkinson's Disease	27
Levodopa‐Carbidopa Intestinal Gel Reduces Dyskinesia in Parkinson's Disease in a Randomized Trial	27
Laryngeal Movement Disorders in Multiple System Atrophy: A Diagnostic Biomarker?	27
Magnetic Susceptibility Associates With Dopaminergic Deficits and Cognition in Parkinson's Disease	27
Salivary α‐Synuclein RT‐QuIC Correlates with Disease Severity in de novo Parkinson's Disease	26
Impact of Subthalamic Deep Brain Stimulation on Impulse Control Disorders in Parkinson's Disease: A Prospective Study	26
Juvenile‐Onset Huntington Disease Pathophysiology and Neurodevelopment: A Review	26
Longitudinal Changes in Parkinson's Disease Symptoms with and Without Rapid Eye Movement Sleep Behavior Disorder: The Oxford Discovery Cohort Study	26
Euglycemia Indicates Favorable Motor Outcome in Parkinson's Disease	26
An Update on the Phenotype, Genotype and Neurobiology of ADCY5‐Related Disease	26
Is Levodopa Response a Valid Indicator of Parkinson's Disease?	26
Brain Motor Network Changes in Parkinson's Disease: Evidence from Meta‐Analytic Modeling	26
Cognitive Behavioral Therapy for Anxiety in Parkinsonʼs Disease: A Randomized Controlled Trial	26
Innovating Parkinson's Care: A Randomized Controlled Trial of Telemedicine Depression Treatment	26
Treatment of *CSF1R*‐Related Leukoencephalopathy: Breaking New Ground	26
Dysregulated Brain Cholesterol Metabolism Is Linked to Neuroinflammation in Huntington's Disease	26
Hypoxia Conditioning as a Promising Therapeutic Target in Parkinson's Disease?	26
Highlighting the Dystonic Phenotype Related to GNAO1	25
α‐Synuclein Radiotracer Development and In Vivo Imaging: Recent Advancements and New Perspectives	25
Echo‐Focusing in Transcranial Focused Ultrasound Thalamotomy for Essential Tremor: A Feasibility Study	25
Elevated In Vitro Kinase Activity in Peripheral Blood Mononuclear Cells of Leucine‐Rich Repeat Kinase 2 G2019S Carriers: A Novel Enzyme‐Linked Immunosorbent Assay–Base	25
GDNF/RET Signaling Pathway Activation Eliminates Lewy Body Pathology in Midbrain Dopamine Neurons	25
Prefrontal Cortex Activity and Gait in Parkinson's Disease With Cholinergic and Dopaminergic Therapy	25
A Gain‐of‐Function Mutation in KCNMA1 Causes Dystonia Spells Controlled With Stimulant Therapy	25
Linking Parkinson's Disease and Melanoma: Interplay Between α‐Synuclein and Pmel17 Amyloid Formation	25
Concomitant Medication Usage with Levodopa‐Carbidopa Intestinal Gel: Results from the COSMOS Study	25
Clinical and Imaging Progression in the PARS Cohort: Long‐Term Follow‐up	25
High Glucosylceramides and Low Anandamide Contribute to Sensory Loss and Pain in Parkinson's Disease	25
Seed Amplification Assay to Diagnose Early Parkinson's and Predict Dopaminergic Deficit Progression	25
Mild Chronic Colitis Triggers Parkinsonism in LRRK2 Mutant Mice Through Activating TNF‐α Pathway	24
Cholinergic Basal Forebrain Volumes Predict Gait Decline in Parkinson's Disease	24
Telemedicine in Movement Disorders: Leçons du COVID‐19	24
Evaluation of Strategies for Measuring Lysosomal Glucocerebrosidase Activity	24
Randomized, Controlled Study of Opicapone in Japanese Parkinson's Patients with Motor Fluctuations	24
Real‐Life Turning Movements Capture Subtle Longitudinal and Preataxic Changes in Cerebellar Ataxia	24
Diabetes, Glycated Hemoglobin (HbA1c), and Neuroaxonal Damage in Parkinson's Disease (MARK‐PD Study)	24
Olfactory Dysfunction in Recovered Coronavirus Disease 2019 (COVID‐19) Patients	24
In Vivo Molecular Signatures of Cerebellar Pathology in Spinocerebellar Ataxia Type 3	24
Gaps, Controversies, and Proposed Roadmap for Research in Normal Pressure Hydrocephalus	24
Inflammation in Experimental Models of α‐Synucleinopathies	24
Relationship of Cerebrospinal Fluid Vitamin B12 Status Markers With Parkinson's Disease Progression	24
Plasma Glucosylsphingosine in GBA1 Mutation Carriers with and without Parkinson's Disease	24
Increased Risk of Parkinson's Disease in Patients With Schizophrenia Spectrum Disorders	24
The Pathophysiological Correlates of Parkinson's Disease Clinical Subtypes	23
Burden of Parkinson's Disease by Severity: Health Care Costs in the U.S. Medicare Population	23
Dopamine D1 Receptors Regulate Spines in Striatal Direct‐Pathway and Indirect‐Pathway Neurons	23
Expanding Data Collection for the MDSGene Database: X‐linked Dystonia‐Parkinsonism as Use Case Example	23
Functional Topography of the Human Subthalamic Nucleus: Relevance for Subthalamotomy in Parkinson's Disease	23
Accurate Detection of α‐Synuclein Seeds in Cerebrospinal Fluid from Isolated Rapid Eye Movement Sleep Behavior Disorder and Patients with Parkinson's Disease in the DeNovo Parkinson (DeNoPa	23
DNAJC6 Mutations Disrupt Dopamine Homeostasis in Juvenile Parkinsonism‐Dystonia	23
Consensus Guidelines on Rodent Models of Restless Legs Syndrome	23
FDG‐PET Patterns Predict Amyloid Deposition and Clinical Profile in Corticobasal Syndrome	23
Parkinson's Disease Modification Through Abl Kinase Inhibition: An Opportunity	23
A Chlorzoxazone‐Baclofen Combination Improves Cerebellar Impairment in Spinocerebellar Ataxia Type 1	23
A Post‐COVID‐19 Parkinsonism in the Future?	23
White Matter Hyperintensities, Dopamine Loss, and Motor Deficits in De Novo Parkinson's Disease	23
Genotype–Phenotype Relations for the Atypical Parkinsonism Genes: MDSGene Systematic Review	23
Implementation of a Novel Bluetooth Technology for Remote Deep Brain Stimulation Programming: The Pre– and Post–COVID‐19 Beijing Experience	23
Profiling the Biochemical Signature of GBA‐Related Parkinson's Disease in Peripheral Blood Mononuclear Cells	22
Clinical Conditions “Suggestive of Progressive Supranuclear Palsy”—Diagnostic Performance	22
Neuroticism and Risk of Parkinson's Disease: A Meta‐Analysis	22
Low Prevalence of NOTCH2NLC GGC Repeat Expansion in White Patients with Movement Disorders	22
Levodopa‐Induced Dyskinesia Are Mediated by Cortical Gamma Oscillations in Experimental Parkinsonism	22
Perampanel Inhibits α‐Synuclein Transmission in Parkinson's Disease Models	22
Disruption of Brainstem Structural Connectivity in REM Sleep Behavior Disorder Using 7 Tesla Magnetic Resonance Imaging	22
Paving the Way Toward Meaningful Trials in Ataxias: An Ataxia Global Initiative Perspective	22
A Randomized, Placebo‐Controlled Crossover Study with Dipyridamole for Restless Legs Syndrome	22
A New MRI Measure to Early Differentiate Progressive Supranuclear Palsy From De Novo Parkinson's Disease in Clinical Practice: An International Study	22
Underrepresented Populations in Parkinson's Genetics Research: Current Landscape and Future Directions	22
Neuroinflammation in the Cerebellum and Brainstem in Friedreich Ataxia: An [¹⁸F]‐FEMPA PET Study	22
Motor Onset Topography and Progression in Parkinson's Disease: the Upper Limb Is First	22
Online Mapping With the Deep Brain Stimulation Lead: A Novel Targeting Tool in Parkinson's Disease	22
Comparison of Locus Coeruleus Pathology with Nigral and Forebrain Pathology in Parkinson's Disease	22
TMEM151A Variants Cause Paroxysmal Kinesigenic Dyskinesia: A Large‐Sample Study	21
Uric Acid in Parkinson′s Disease: What Is the Connection?	21
Abstract	21
Novel Programming Features Help Alleviate Subthalamic Nucleus Stimulation‐Induced Side Effects	21
Availability of Therapies and Services for Parkinson's Disease in Africa: A Continent‐Wide Survey	21
Nicotinamide Riboside Improves Ataxia Scores and Immunoglobulin Levels in Ataxia Telangiectasia	21
Safety and Efficacy of Mevidalen in Lewy Body Dementia: A Phase 2, Randomized, Placebo‐Controlled Trial	21
The Emerging Role of Phosphodiesterases in Movement Disorders	21
Cerebrospinal α‐Synuclein Oligomers Reflect Disease Motor Severity in DeNoPa Longitudinal Cohort	21
Polyglutamine‐Expanded Ataxin‐3: A Target Engagement Marker for Spinocerebellar Ataxia Type 3 in Peripheral Blood	21
Visual Impairment Is More Common in Parkinson’s Disease and Is a Risk Factor for Poor Health Outcomes	21
Dietary Antioxidants and Risk of Parkinson's Disease in the Singapore Chinese Health Study	21
Striatal Dopamine Deficit and Motor Impairment in Idiopathic Normal Pressure Hydrocephalus	21
A Double‐Blind, Randomized, Controlled Trial of Lovastatin in Early‐Stage Parkinson's Disease	21
Magnetic Resonance‐Guided Focused Ultrasound Thalamotomy for Focal Hand Dystonia: A Pilot Study	21
Motor Cortical Network Excitability in Parkinson's Disease	21
Apolipoprotein E Genotype Contributes to Motor Progression in Parkinson's Disease	21
Idiopathic Non‐task‐Specific Upper Limb Dystonia, a Neglected Form of Dystonia	21
Mutation Analysis of DNAJC Family for Early‐Onset Parkinson's Disease in a Chinese Cohort	21
Translating Evidence to Advanced Parkinson's Disease Patients: A Systematic Review and Meta‐Analysis	21
Onset of Skin, Gut, and Genitourinary Prodromal Parkinson's Disease: A Study of 1.5 Million Veterans	21
Adaptive Deep Brain Stimulation: From Experimental Evidence Toward Practical Implementation	21